ORIC Pharmaceuticals competitors

J Scott Wolchko are a President/CEO/COO at FATE THERAPEUTICS INC and Board Member at FATE THERAPEUTICS INC. They have worked as Chief Financial Officer at Bocada and VP:Operations/CFO at FATE THERAPEUTICS INC. J studied at University of Virginia and Alpha Omega Alpha Medical Honor Society.

Paula Brown Stafford is a biopharmaceutical services executive and leadership consultant with more than 30 years of industry experience. She is currently the President and Chief Operating Officer for Novan, Inc., as well as a Managing Director for Habergeon LLC. Ms. Stafford retired in 2015 from her position as President of Clinical Development at Quintiles (now part of iQvia). Ms. Stafford’s global responsibilities encompassed Phase I-IV clinical research services and she served as a member of Quintiles Executive Committee. She was an Independent Director for BioImaging, later BioClinica (NASDAQ: BIOC), from 2002 to 2008. In addition, Ms. Stafford served as a member of the CDISC (Clinical Data Interchange Standards Consortium) Board of Directors for 9 years, serving as Chair for 2 years and as a member of the Executive Committee for 6 years. Ms. Stafford is an Adjunct Professor in Public Health Leadership for the UNC-CH Gillings School of Global Public Health and emeritus member of the UNC-CH Public Health Foundation Board. In 2011, Ms. Stafford received the Triangle Business Journal’s Women in Business Award. FierceBiotech named Ms. Stafford one of the 10 top women in biotech in 2012. Ms. Stafford holds a Bachelor of Science and a Master of Public Health in Biostatistics from the University of North Carolina at Chapel Hill. In 2016, the university honored Ms. Stafford with its Distinguished Alumna Award.

Dr. Peltz founded PTC Therapeutics in 1998 and has served as Chief Executive Officer and a member of the board of directors since the company’s inception. Under his leadership, PTC has grown from a research organization to a publicly traded, global commercial organization with multiple approved products and a foundation of strong technology platforms that continues to drive a robust discovery pipeline for patients with rare disorders. Prior to founding PTC, Dr. Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. Dr. Peltz is a recognized scientific leader in RNA biology in the area of post-transcriptional control processes involving mRNA turnover and translation, with more than 30 years of research and over 100 publications in this area. Dr. Peltz has received a number of business and scientific awards. Notably, he was elected as a Fellow of the American Academy for the Advancement of Science in 2010. He was recognized as PharmaVoice’s 100 Most Inspiring People in 2009 and received the Dr. Sol J. Barer Award for Vision Innovation and Leadership in 2014. Dr. Peltz received a Ph.D. from the McArdle Laboratory for Cancer Research at the University of Wisconsin.

Martin Driscoll is a Chairman, President and Chief Executive Officer at Spring Bank Pharmaceuticals Inc and is based in Hopkinton, Massachusetts.

Steven L. Hoerter has served as our Senior Vice President, Commercial since August 2011. From 2010 to 2011, Steven Hoerter was General Manager and Management Center Head at F. Hoffmann-La Roche Ltd. for the Sub-Saharan Africa and Indian Ocean Region, based in Johannesburg, South Africa. From 2005 to 2010, Steven Hoerter held a variety of positions at Genentech, Inc., including serving on the senior leadership team for Genentech's BioOncology business as Senior Director, Pipeline Development and Commercial Operations. Prior to that he worked at Chiron Corporation and Eli Lilly and Company. During Steven Hoerter's 11-year career at Lilly, he held positions in sales, business development, marketing and business unit management in the US, Europe and Africa. Steven Hoerter has a B.A. in Russian and Political Science from Bucknell University, an M.B.A. from Tilburg University and a M.S. in Management from Purdue University.

Jigar Raythatha joined Jounce Therapeutics in December 2012 after a 15 year career in the biotechnology industry in a variety business functions. Most recently, Jigar Raythatha was the head of corporate development of Constellation Pharmaceuticals, Inc. where he was instrumental in securing over $175 million in non-dilutive and equity funding. In addition, Jigar Raythatha negotiated and subsequently led the company's broad epigenetics strategic alliance with Genentech and established Constellation's project management and market development capabilities. Prior to Constellation, Jigar Raythatha worked with Red Abbey Venture Partners, initially as a Kauffman fellow, later as a principal, and finally a venture partner. During his tenure at Red Abbey, Jigar Raythatha led or participated in all of the firm's investments, including Advanced BioHealing (acquired by Shire), Aegerion Pharmaceuticals (IPO), Cogenesys (acquired by Teva), and Stromedix (acquired by Biogen Idec). Previously, Jigar Raythatha has worked with Biogen, Inc. and Pfizer, Inc. in business development and new product planning roles. Jigar Raythatha holds an M.B.A. from Columbia Business School and a B.A. in molecular biology and biochemistry and economics from Rutgers University.

Dr. Worland has served as a member of the board of directors since February 2015. Dr. Worland is currently President and Chief Executive Officer and a director of eFFECTOR Therapeutics, Inc., a company focused on new treatments for cancer, where he has served since May 2012. Previously, Dr. Worland was President and Chief Executive Officer and a director of Anadys Pharmaceuticals, Inc., a biopharmaceutical company which discovered and developed treatments for hepatitis C and cancer, from August 2007 until the company’s acquisition by Roche in November 2011. Dr. Worland joined Anadys in 2001 and served in a number of executive roles prior to being named Chief Executive Officer, including President, Pharmaceuticals, and Chief Scientific Officer. Dr. Worland began his healthcare industry career at Agouron Pharmaceuticals, Inc. and remained with the company through its successful commercialization of an HIV protease inhibitor and successive acquisitions by Warner-Lambert and Pfizer. During this period, Dr. Worland held a number of positions, including Vice President, Antiviral Research and Director, Molecular Biology and Biochemistry. Dr. Worland was a National Institutes of Health Postdoctoral Fellow in Molecular Biology at Harvard University. Dr. Worland received his B.S. with highest honors in Biological Chemistry from the University of Michigan and his Ph.D. in Chemistry from the University of California, Berkeley.